

Raymond L Rosales

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/663645/publications.pdf>

Version: 2024-02-01

98
papers

2,256
citations

236925

25
h-index

243625

44
g-index

111
all docs

111
docs citations

111
times ranked

2114
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study. <i>International Journal of Neuroscience</i> , 2024, 134, 131-136.	1.6	0
2	Temperature sensation in Parkinson's disease measured by quantitative sensory testing: a single-center, case-control study. <i>International Journal of Neuroscience</i> , 2023, 133, 834-839.	1.6	2
3	Mosaic divergent repeat interruptions in XDP influence repeat stability and disease onset. <i>Brain</i> , 2023, 146, 1075-1082.	7.6	10
4	A mixed-ethnicity myoclonus-dystonia patient with a novel SGCE nonsense mutation: a case report. <i>BMC Neurology</i> , 2022, 22, 11.	1.8	0
5	Calpainopathy (Leyden-Mobius Limb-Girdle Muscular Dystrophy Type 2A Phenotype) and Dysferlinopathy (Miyoshi Distal Myopathy Limb-Girdle Muscular Dystrophy Type 2B Phenotype) of Preadolescent Onset: Case Reports of Two Male Filipinos. <i>Cureus</i> , 2022, 14, e21353.	0.5	1
6	Lewy body disease or diseases with Lewy bodies?. <i>Npj Parkinson's Disease</i> , 2022, 8, 3.	5.3	26
7	Elucidating Hexanucleotide Repeat Number and Methylation within the X-Linked Dystonia-Parkinsonism (XDP)-Related SVA Retrotransposon in TAF1 with Nanopore Sequencing. <i>Genes</i> , 2022, 13, 126.	2.4	9
8	Transcriptional Alterations in X-Linked Dystonia-Parkinsonism Caused by the SVA Retrotransposon. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2231.	4.1	6
9	Botulinum Neurotoxin A for Hand Tremors in Parkinson's Disease: A Meta-Analytic Study. <i>Journal of Medicine University of Santo Tomas</i> , 2022, 6, 814-822.	0.1	0
10	No Pain No Gain - Quest for Academic and Research Excellence. <i>Journal of Medicine University of Santo Tomas</i> , 2022, 6, 813-813.	0.1	0
11	Reply: Matters Arising ~Lewy body disease or diseases with Lewy bodies?. <i>Npj Parkinson's Disease</i> , 2022, 8, .	5.3	0
12	Botulinum toxin therapy of dystonia. <i>Journal of Neural Transmission</i> , 2021, 128, 531-537.	2.8	14
13	A Cross-Cultural Validation of the Filipino and Hiligaynon Versions of the Parts IIIB (Non-Motor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Clinical Parkinsonism & Related Disorders, 2021, 5, 100100.	0.9	1
14	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. <i>Journal of Neural Transmission</i> , 2021, 128, 321-335.	2.8	37
15	Contemporary clinical neurophysiology applications in dystonia. <i>Journal of Neural Transmission</i> , 2021, 128, 509-519.	2.8	4
16	X-linked dystonia Parkinsonism: crossing a new threshold. <i>Journal of Neural Transmission</i> , 2021, 128, 567-573.	2.8	7
17	Untwisting dystonia: stepping-up genetics, shifting pathophysiology, and strategizing care. <i>Journal of Neural Transmission</i> , 2021, 128, 393-394.	2.8	0
18	Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. <i>Scientific Reports</i> , 2021, 11, 9611.	3.3	21

#	ARTICLE	IF	CITATIONS
19	Identifying genetic modifiers of age-associated penetrance in X-linked dystonia-parkinsonism. <i>Nature Communications</i> , 2021, 12, 3216.	12.8	34
20	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 48.	5.3	23
21	Brain Regional Differences in Hexanucleotide Repeat Length in X-Linked Dystonia-Parkinsonism Using Nanopore Sequencing. <i>Neurology: Genetics</i> , 2021, 7, e608.	1.9	18
22	Pain in cervical dystonia: mechanisms, assessment and treatment. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1125-1134.	2.8	18
23	Physician-Scientist, Academician and Published Research Author. <i>Journal of Medicine University of Santo Tomas</i> , 2021, 5, 670-670.	0.1	0
24	Constrictive Entrapment Neuropathies of a Limb Secondary to Restraint Strapping: A Case Report. <i>Journal of Medicine University of Santo Tomas</i> , 2021, 5, 798-801.	0.1	0
25	Viewpoint: Physician as a Clinician, Researcher, and Academician. <i>Journal of Medicine University of Santo Tomas</i> , 2021, 5, 671-674.	0.1	0
26	<sc>DNA</sc> Methylation as a Potential Molecular Mechanism in X-Linked Dystonia-Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 2220-2229.	3.9	7
27	Expanding Data Collection for the <sc>MDSGene</sc> Database: X-Linked Dystonia-Parkinsonism as Use Case Example. <i>Movement Disorders</i> , 2020, 35, 1933-1938.	3.9	23
28	Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study. <i>Journal of Neural Transmission</i> , 2020, 127, 935-951.	2.8	17
29	Delivering patient-centered care in Parkinson's disease: Challenges and consensus from an international panel. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 82-87.	2.2	25
30	Clinical practice with steroid therapy for Duchenne muscular dystrophy: An expert survey in Asia and Oceania. <i>Brain and Development</i> , 2020, 42, 277-288.	1.1	7
31	Preparing for the Expected. <i>Journal of Medicine University of Santo Tomas</i> , 2020, 4, 477-478.	0.1	0
32	Scientific Publishing: Vital for Public Health and Authors. <i>Journal of Medicine University of Santo Tomas</i> , 2020, 4, 393-393.	0.1	0
33	Imaging gradual neurodegeneration in a basal ganglia model disease. <i>Annals of Neurology</i> , 2019, 86, 517-526.	5.3	23
34	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , The, 2019, 18, 865-879.	10.2	116
35	A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism. <i>Annals of Neurology</i> , 2019, 85, 812-822.	5.3	67
36	Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis. <i>Journal of Neural Transmission</i> , 2019, 126, 141-148.	2.8	13

#	ARTICLE	IF	CITATIONS
37	Eye movement deficits in X-linked dystonia-parkinsonism are related to striatal degeneration. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 170-178.	2.2	12
38	Association of Pallidal Neurostimulation and Outcome Predictors With X-linked Dystonia Parkinsonism. <i>JAMA Neurology</i> , 2019, 76, 211.	9.0	36
39	Long-term outcomes of pallidal deep brain stimulation in X-linked dystonia parkinsonism (XDP): Up to 84 months follow-up and review of literature. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 81-86.	2.2	23
40	Time to Ride the Wave of Precision Medicine. <i>Journal of Medicine University of Santo Tomas</i> , 2019, 3, 245-247.	0.1	0
41	Mileage in Research Collaboration. <i>Journal of Medicine University of Santo Tomas</i> , 2019, 3, .	0.1	0
42	Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. <i>Cell</i> , 2018, 172, 897-909.e21.	28.9	163
43	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. <i>Journal of Neurology</i> , 2018, 265, 856-862.	3.6	51
44	The Basal Ganglia Striosomes Affect the Modulation of Conflicts by Subliminal Information—Evidence from X-Linked Dystonia Parkinsonism. <i>Cerebral Cortex</i> , 2018, 28, 2243-2252.	2.9	29
45	Increased insula-putamen connectivity in X-linked dystonia-parkinsonism. <i>NeuroImage: Clinical</i> , 2018, 17, 835-846.	2.7	23
46	Botulinum neurotoxin for lip and tongue dystonia: “Drooling along the way”. <i>Toxicon</i> , 2018, 156, S98.	1.6	0
47	Basal ganglia and cerebellar pathology in X-linked dystonia-parkinsonism. <i>Brain</i> , 2018, 141, 2995-3008.	7.6	41
48	Genome editing in induced pluripotent stem cells rescues <i>TAF1</i> levels in X-linked dystonia-parkinsonism. <i>Movement Disorders</i> , 2018, 33, 1108-1118.	3.9	35
49	Treatment of oromandibular dystonia using botulinum toxin injections “ Case series and illustrative muscle targeting. <i>Basal Ganglia</i> , 2018, 13, 7-16.	0.3	5
50	Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. <i>Toxins</i> , 2018, 10, 253.	3.4	31
51	Ostinato Rigore in Research - Message from The Editor-In Chief. <i>Journal of Medicine University of Santo Tomas</i> , 2018, 2, 120-120.	0.1	0
52	Acute Ischemic Stroke in a Filipino with Parkinsonian Fahr’s Disease: A Case Report. <i>Journal of Medicine University of Santo Tomas</i> , 2018, 2, 220-223.	0.1	0
53	Filipino Version of Penn Facial Pain Scale: Phase 1 Validation Study. <i>Journal of Medicine University of Santo Tomas</i> , 2018, 2, .	0.1	0
54	Striosomal dysfunction affects behavioral adaptation but not impulsivity—Evidence from X-linked dystonia-parkinsonism. <i>Movement Disorders</i> , 2017, 32, 576-584.	3.9	37

#	ARTICLE	IF	CITATIONS
55	Sonographic alteration of substantia nigra is related to parkinsonism-predominant course of X-linked dystonia-parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 43-49.	2.2	12
56	Dysfunctions in striatal microstructure can enhance perceptual decision making through deficits in predictive coding. <i>Brain Structure and Function</i> , 2017, 222, 3807-3817.	2.3	12
57	Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia: Results from Patient and Physician Surveys. <i>Advances in Therapy</i> , 2017, 34, 1426-1437.	2.9	29
58	Effect of early use of AbobotulinumtoxinA after stroke on spasticity progression: Protocol for a randomised controlled pilot study in adult subjects with moderate to severe upper limb spasticity (ONTIME pilot). <i>Contemporary Clinical Trials Communications</i> , 2017, 6, 9-16.	1.1	3
59	Botulinum toxin therapy as an early intervention for post-stroke spasticity: Beyond a functional viewpoint. <i>Journal of the Neurological Sciences</i> , 2017, 382, 187-188.	0.6	5
60	Nonmotor Symptoms in Dystonia. <i>International Review of Neurobiology</i> , 2017, 134, 1335-1371.	2.0	20
61	Validation of the XDP-MDSP rating scale for the evaluation of patients with X-linked dystonia-parkinsonism. <i>Npj Parkinson's Disease</i> , 2017, 3, 24.	5.3	18
62	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. <i>Journal of Neurology</i> , 2017, 264, 112-120.	3.6	32
63	Post-Varicella Acute Inflammatory Demyelinating Polyradiculoneuropathy in a 51-year old Filipino Male: A Case Report. <i>Journal of Medicine University of Santo Tomas</i> , 2017, 1, 93-97.	0.1	0
64	Botulinum Toxin Injection for Pain in Muscle Spasm and Visceromotor Disorders: A Meta-Analytic Study. <i>Journal of Medicine University of Santo Tomas</i> , 2017, 1, 69-78.	0.1	1
65	Prevalence and Predisposing Factors of Parkinson Disease: A Community-Based Study In Barangay Mangilag Sur, Candelaria, Quezon: A Research Protocol. <i>Journal of Medicine University of Santo Tomas</i> , 2017, 1, 109-119.	0.1	1
66	Recurrent Bilateral Neuropathy in a Case of Steroid Responsive Neurosarcoidosis: A Case Report. <i>Journal of Medicine University of Santo Tomas</i> , 2017, 1, 87-92.	0.1	0
67	Baseline characteristics of patients from a pilot study to assess the effect of early use of abobotulinumtoxinA (Dysport®) after stroke on spasticity progression. <i>Toxicon</i> , 2016, 123, S71.	1.6	0
68	Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 3205-3215.	5.4	37
69	Botulinum toxin as early intervention for spasticity after stroke or non-progressive brain lesion: A meta-analysis. <i>Journal of the Neurological Sciences</i> , 2016, 371, 6-14.	0.6	65
70	Neuroanatomical changes extend beyond striatal atrophy in X-linked dystonia parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 91-97.	2.2	42
71	RAB39B mutations are a rare finding in Parkinson disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 116-117.	2.2	13
72	Strategies for treatment of dystonia. <i>Journal of Neural Transmission</i> , 2016, 123, 251-258.	2.8	31

#	ARTICLE	IF	CITATIONS
73	How Can We Improve Current Practice in Spastic Paresis?. European Neurological Review, 2016, 11, 79.	0.5	11
74	Successfully Treated Waldenstrom Macroglobulinemia with Nine-year Follow-up: Case Report and Review of Neurologic Manifestations. Journal of Neurological Disorders, 2016, 4, .	0.1	0
75	171. Botulinum neurotoxin injections for oromandibular dystonias. Toxicon, 2015, 93, S53.	1.6	0
76	45. An international, prospective cohort to document the effectiveness of 1 cycle of BoNT/A based on attainment of individual person-centered goals in adult subjects suffering from upper limb spasticity following stroke (ULIS II): subanalysis of the South Asian group of spasticity patients. Toxicon, 2015, 93, S15-S16.	1.6	0
77	First Report of a Filipino with Mohr-Tranebjaerg Syndrome. Movement Disorders Clinical Practice, 2015, 2, 417-419.	1.5	6
78	Neurophysiological fingerprints of X-linked dystonia-parkinsonism: A model basal ganglia disease. Movement Disorders, 2015, 30, 873-875.	3.9	11
79	A Case Report on Dyskinesia Following Rivastigmine Patch 13.3mg/24hours for Alzheimer's Disease. Medicine (United States), 2015, 94, e1364.	1.0	8
80	New insights into the genetics of X-linked dystonia-parkinsonism (XDP, DYT3). European Journal of Human Genetics, 2015, 23, 1334-1340.	2.8	73
81	Dystonia: The Syndrome, Its Term, Concept and Their Evolution. , 2015, , 3-12.		0
82	Dystonia-Parkinsonism Syndromes. , 2015, , 75-88.		0
83	Woman With X-Linked Recessive Dystonia-Parkinsonism. JAMA Neurology, 2014, 71, 1177.	9.0	24
84	Mutations in <i>GNAL</i> . JAMA Neurology, 2014, 71, 490.	9.0	70
85	Mental Dysfunctions in Dystonia-Plus Syndromes. Journal of Parkinson's Disease, 2014, 4, 161-167.	2.8	3
86	Botulinum Toxin Injection for Hypertonicity of the Upper Extremity Within 12 Weeks After Stroke. Neurorehabilitation and Neural Repair, 2012, 26, 812-821.	2.9	106
87	What's the "catch" in upper-limb post-stroke spasticity: Expanding the role of botulinum toxin applications. Parkinsonism and Related Disorders, 2011, 17, S3-S10.	2.2	22
88	Cilostazol: A Pilot Study on Safety and Clinical Efficacy in Neuropathies of Diabetes Mellitus Type 2 (ASCEND). Angiology, 2011, 62, 625-635.	1.8	9
89	Uncovering the Mystery From the Philippine Island of Panay. International Journal of Neuroscience, 2011, 121, 1-2.	1.6	13
90	The Unique Phenomenology of Sex-Linked Dystonia Parkinsonism (XDP, DYT3, "Lubag"). International Journal of Neuroscience, 2011, 121, 3-11.	1.6	130

#	ARTICLE	IF	CITATIONS
91	Untreated Depressive Symptoms Among Cognitively-Intact, Community Dwelling Filipino Patients With Parkinson Disease. <i>International Journal of Neuroscience</i> , 2011, 121, 137-141.	1.6	9
92	The Broadening Application of Chemodenervation in X-Linked Dystonia-Parkinsonism (Part I): Muscle Afferent Block Versus Botulinum Toxin-A in Cervical and Limb Dystonias. <i>International Journal of Neuroscience</i> , 2011, 121, 35-43.	1.6	16
93	The Broadening Application of Chemodenervation in X-Linked Dystonia-Parkinsonism (Part II): An Open-Label Experience With Botulinum Toxin-A (Dysport®) Injections for Oromandibular, Lingual, and Truncal-Axial Dystonias. <i>International Journal of Neuroscience</i> , 2011, 121, 44-56.	1.6	32
94	X-Linked Dystonia Parkinsonism: Clinical Phenotype, Genetics and Therapeutics. <i>Journal of Movement Disorders</i> , 2010, 3, 32-38.	1.3	33
95	The Occurrence of Fatigue in Independent and Clinically Stable Filipino Patients with Idiopathic Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2009, 2, 18-21.	1.3	4
96	Novel <i>PINK1</i> mutations in early-onset parkinsonism. <i>Annals of Neurology</i> , 2004, 56, 424-427.	5.3	247
97	Genetic mapping of ?Lubag? (X-linked dystonia-parkinsonism) in a filipino kindred to the pericentromeric region of the X chromosome. <i>Annals of Neurology</i> , 1991, 29, 124-131.	5.3	89
98	Indirect Central Nervous System Effects of Botulinum Toxin. , 0, , 106-110.		1